The Protein Brewery’s Fermotein Wins EU Novel Food Authorisation as First Approved Mycelium Ingredient

Why It Matters

The approval opens Europe’s largest market to a new, sustainable protein source, accelerating the shift toward plant‑based alternatives and establishing a regulatory precedent for future mycelium foods.

Key Takeaways

• First mycelium ingredient approved under EU Novel Food framework
• Six‑year approval timeline highlights regulatory bottlenecks for food innovation
• Fermotein delivers 50% protein, 30% fiber, plus micronutrients
• Company targets 600 t in 2027, >2,000 t by 2029
• EU clearance enables direct supply to European brands, boosting market adoption

Pulse Analysis

The European Union’s Novel Food Regulation, enacted in 2015, has long served as a gatekeeper for emerging food ingredients, demanding rigorous safety assessments by EFSA before market entry. The Protein Brewery’s recent approval of Fermotein—a mycelium derived from Rhizomucor pusillus—marks the first time a fungal biomass has cleared this pathway, setting a benchmark for future mycoprotein innovations. The six‑year journey from dossier submission in 2020 to the Commission’s implementing regulation in June 2026 underscores both the thoroughness of the process and the need for faster scientific advice to keep pace with rapid product development.

Fermotein’s nutritional profile—roughly 50 % complete protein, 30 % dietary fiber and a suite of naturally occurring micronutrients—positions it as a versatile ingredient for protein powders, dairy‑free beverages, and fortified snacks. Compared with traditional animal protein, mycelium fermentation requires far less land and water, and it generates lower greenhouse‑gas emissions, aligning with EU sustainability goals and consumer demand for clean‑label alternatives. The ingredient’s fungal origin also offers functional benefits such as emulsification and texture enhancement, allowing manufacturers to replace multiple additives with a single, clean component.

With EU clearance secured, The Protein Brewery plans to ship 600 tonnes of Fermotein from its Breda facility in 2027, scaling to over 2,000 tonnes by 2029 to meet commitments from European, U.S., and Singaporean brands. Direct supply from a Dutch plant reduces logistical complexity and carbon footprint, giving European manufacturers a locally sourced, high‑quality protein alternative. The approval also signals to investors that mycelium‑based foods can navigate the EU’s stringent regulatory landscape, likely spurring additional R&D funding and accelerating the broader rollout of fungal proteins across the continent.